Mergers & Acquisitions ·
HUTCHMED closes KRAS-EGFR antibody conjugate license to GSK for $110M upfront and up to $1.185B in milestones
HMDCFHUTCHMED (China) Ltd
HUTCHMED (China) Limited announced the closing of an exclusive development and license agreement with a subsidiary of GSK plc for its KRAS-EGFR antibody conjugate therapy candidate, HMPL-A830. The deal grants GSK worldwide rights outside Mainland China, Hong Kong, Macau, and Taiwan to develop and commercialize the drug following the completion of customary closing conditions, including antitrust regulatory reviews. HUTCHMED Limited retains responsibility for the global Phase I development program, while GSK will manage subsequent clinical development and commercialization in its territory. Under the agreement terms, HUTCHMED expects to receive a US$110 million upfront payment shortly upon closing. The company may also receive additional development, regulatory, and commercial milestone payments totaling up to US$1.185 billion, along with tiered royalties on annual net sales. This transaction represents a significant strategic partnership for the biopharmaceutical company, which focuses on the discovery and global development of targeted therapies and immunotherapies for cancer and immunological diseases.